Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents. IUIS Committee on Primary Immunodeficiency Disease. International Union of Immunological Societies

Review

H M Chapel. Clin Exp Immunol. 1999 Oct.

. 1999 Oct;118 Suppl 1(Suppl 1):29-34.

doi: 10.1046/j.1365-2249.1999.00000.x.

No abstract available

References

1. Milgrom H. Shortages of intravenous immunoglobulin. Ann Allergy, Asthma Immunol. 1998;81:97–9. - PubMed
1. Cohn EJ, Strong LE, Hughes WL. Preparation and properties of serum and plasma proteins IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. Ann Am Chem Soc Year. 1946;68:459–7. - PubMed
1. Yap PL. Viral Safety of IVIg. In: Lee M, Stand V, editors. Intravenous Immunoglobulin in Clinical Practice. 1997. pp. 67–10. Marcel Dekker.
1. Mitra G, Wong MF, Mozen MM, McDougal FS, Levy JA. Elimination of infectious retroviruses during preparation of immunoglobulin. Transfusion. 1986;26:394–7. - PubMed
1. Wells MA, Wittek AE, Epstein JS. Inactivation and partition of human T cell lymphotrophic virus, type III, during ethanol fractionation of plasma. Transfusion. 1986;26:210–3. - PubMed